218 related articles for article (PubMed ID: 34209090)
1. A Personalized Genomics Approach of the Prostate Cancer.
Iacobas S; Iacobas DA
Cells; 2021 Jun; 10(7):. PubMed ID: 34209090
[TBL] [Abstract][Full Text] [Related]
2. Personalized 3-Gene Panel for Prostate Cancer Target Therapy.
Iacobas S; Iacobas DA
Curr Issues Mol Biol; 2022 Jan; 44(1):360-382. PubMed ID: 35723406
[TBL] [Abstract][Full Text] [Related]
3. The Gene Master Regulators (GMR) Approach Provides Legitimate Targets for Personalized, Time-Sensitive Cancer Gene Therapy.
Iacobas S; Ede N; Iacobas DA
Genes (Basel); 2019 Jul; 10(8):. PubMed ID: 31349573
[TBL] [Abstract][Full Text] [Related]
4. Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer.
Amir S; Ma AH; Shi XB; Xue L; Kung HJ; Devere White RW
PLoS One; 2013; 8(4):e61064. PubMed ID: 23585871
[TBL] [Abstract][Full Text] [Related]
5. TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer.
Takayama KI; Suzuki T; Tanaka T; Fujimura T; Takahashi S; Urano T; Ikeda K; Inoue S
Oncogene; 2018 Apr; 37(16):2165-2180. PubMed ID: 29379164
[TBL] [Abstract][Full Text] [Related]
6. Long intragenic non-coding RNA lincRNA-p21 suppresses development of human prostate cancer.
Wang X; Ruan Y; Wang X; Zhao W; Jiang Q; Jiang C; Zhao Y; Xu Y; Sun F; Zhu Y; Xia S; Xu D
Cell Prolif; 2017 Apr; 50(2):. PubMed ID: 27976428
[TBL] [Abstract][Full Text] [Related]
7. Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
Dozmorov MG; Azzarello JT; Wren JD; Fung KM; Yang Q; Davis JS; Hurst RE; Culkin DJ; Penning TM; Lin HK
BMC Cancer; 2010 Dec; 10():672. PubMed ID: 21134280
[TBL] [Abstract][Full Text] [Related]
8. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
9. Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin.
Zhang Y; Dong Y; Melkus MW; Yin S; Tang SN; Jiang P; Pramanik K; Wu W; Kim S; Ye M; Hu H; Lu J; Jiang C
Mol Cancer Ther; 2018 Nov; 17(11):2341-2352. PubMed ID: 30166403
[TBL] [Abstract][Full Text] [Related]
10. Short hairpin RNA library-based functional screening identified ribosomal protein L31 that modulates prostate cancer cell growth via p53 pathway.
Maruyama Y; Miyazaki T; Ikeda K; Okumura T; Sato W; Horie-Inoue K; Okamoto K; Takeda S; Inoue S
PLoS One; 2014; 9(10):e108743. PubMed ID: 25285958
[TBL] [Abstract][Full Text] [Related]
11. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer.
Eastham JA; Grafton W; Martin CM; Williams BJ
J Urol; 2000 Sep; 164(3 Pt 1):814-9. PubMed ID: 10953161
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells.
Singh AP; Bafna S; Chaudhary K; Venkatraman G; Smith L; Eudy JD; Johansson SL; Lin MF; Batra SK
Cancer Lett; 2008 Jan; 259(1):28-38. PubMed ID: 17977648
[TBL] [Abstract][Full Text] [Related]
13. RNA interference targeting mutant p53 inhibits growth and induces apoptosis in DU145 human prostate cancer cells.
Zhu H; Mao Q; Lin Y; Yang K; Xie L
Med Oncol; 2011 Dec; 28 Suppl 1():S381-7. PubMed ID: 20857345
[TBL] [Abstract][Full Text] [Related]
14. Sanggenol L Induces Apoptosis and Cell Cycle Arrest via Activation of p53 and Suppression of PI3K/Akt/mTOR Signaling in Human Prostate Cancer Cells.
Won YS; Seo KI
Nutrients; 2020 Feb; 12(2):. PubMed ID: 32075054
[TBL] [Abstract][Full Text] [Related]
15. Genomic Fabric Remodeling in Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): A New Paradigm and Proposal for a Personalized Gene Therapy Approach.
Iacobas DA; Mgbemena VE; Iacobas S; Menezes KM; Wang H; Saganti PB
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33302383
[TBL] [Abstract][Full Text] [Related]
16. Androgen action during prostate carcinogenesis.
Wang D; Tindall DJ
Methods Mol Biol; 2011; 776():25-44. PubMed ID: 21796518
[TBL] [Abstract][Full Text] [Related]
17. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.
Gao X; Porter AT; Honn KV
Adv Exp Med Biol; 1997; 407():41-53. PubMed ID: 9321930
[TBL] [Abstract][Full Text] [Related]
18. Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.
Singh S; Chitkara D; Mehrazin R; Behrman SW; Wake RW; Mahato RI
PLoS One; 2012; 7(6):e40021. PubMed ID: 22768203
[TBL] [Abstract][Full Text] [Related]
19. Adeno-associated virus 2-mediated intratumoral prostate cancer gene therapy: long-term maspin expression efficiently suppresses tumor growth.
Watanabe M; Nasu Y; Kashiwakura Y; Kusumi N; Tamayose K; Nagai A; Sasano T; Shimada T; Daida H; Kumon H
Hum Gene Ther; 2005 Jun; 16(6):699-710. PubMed ID: 15960601
[TBL] [Abstract][Full Text] [Related]
20. RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer.
Ren C; Li L; Yang G; Timme TL; Goltsov A; Ren C; Ji X; Addai J; Luo H; Ittmann MM; Thompson TC
Cancer Res; 2004 Feb; 64(3):969-76. PubMed ID: 14871827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
